卫生部心血管分子生物学和调节肽卫生部重点实验室（原为卫生部心肺内分泌调节肽重点实验室）于1984年筹建，1986年通过验收并向全国开放。历任实验室主任为汤健教授、韩启德院士。实验室名誉主任为韩启德院士，现任实验室主任为高炜教授，学术委员会主任为张运院士。

　　重点实验室的主要研究方向是冠心病的危险因素防治和冠心病及其并发症诊疗/康复及转化医学研究，围绕疾病的危险及致病因素、疾病的发生、发展的分子机制，开展基础与临床双向结合的转化医学研究。主要包括1）早预防：揭示冠心病及其并发症易感基因及新的危险因素；2）早预警：明确冠心病及其并发症新的早期生物标志物；3）早治疗：深化研究冠心病及其并发症治疗的新技术、新方法和新靶点；4）早康复：阐明冠心病及其并发症康复训练的保护作用及机制，提出早预警、早诊断、早治疗、早康复的依据和方案，开发可用于疾病防治的新技术和药物新靶点，为降低中国人口心血管事件发生率和提高心血管病患者的生存质量提供科学依据和新策略。

　　实验室人才队伍的结构情况：现有固定人员60人，其中专职科研人员52人，技术人员8人；长江学者2人、入选国家自然科学基金委杰出青年项目4人、优秀青年项目3人，获得北京市科技新星称号1人、中组部“万人计划”青年拔尖人才1人；正高级职称26名，副高级职称19名，具有博士学位49名，具有硕士学位7人；20余人有在国外做博士后或访问学者的经历。长期以来重点实验室PI的学术水平被国内外学术界认可和重视，有多人被选为重要的国际、国内学术组织主席、副主席、秘书长；多人受聘为国际、国内刊物编委。

　　实验室建筑面积2140m²，仪器设备总值超过3000万元。近年实验室建立完善了多个研究平台，包括形态影像平台（含组织形态学平台、细胞影像学平台）、生化代谢检测技术平台、蛋白质组/代谢组学检测技术平台、心血管模型功能评价平台（超声心动图检测、血管张力生理记录系统等）。临床研究方面，建立完善了心肺康复治疗评价平台、心血管疾病药物临床研究平台、心血管疾病生物样本库。

　　重点实验室近年研究成果分别获得“2015年度华夏医学科技奖”一等奖1项、2017年度国家自然科学奖二等奖1项、2017年度教育部自然科学一等奖1项等；两名重点实验室PI先后荣获“药明康德生命化学研究奖”学者奖。

　　在冠心病危险因素的防治研究方面，针对高同型半胱氨酸血症与动脉粥样硬化防治的研究成果提供了国人特有的高同型半胱氨酸血症作为血管疾病的危险因素的实验证据，同时转化到临床研究中，开展了十二五“中国人群冠心病优化治疗的研究”项目，为我国冠心病患者优化治疗做出突出贡献。在冠心病及其并发症诊疗/康复及转化医学研究方面，我们围绕心血管受体与疾病的发生发展的分子机制、心力衰竭的早期分子机制和潜在诊治靶点以及疾病的生物标志物研究，从冠心病及心力衰竭的诊治和预警各层面，开展了基础和临床研究，开发可用于疾病防治的新技术和药物新靶点，为降低中国人口心血管事件发生率和提高心血管病患者的生存质量提供科学依据和新策略。

　　

　　机构负责人：高炜

　　联系人：于海奕

　　邮箱：bysyxnk@163.com

　　电话：010-82266711

　　地址：北京市海淀区花园北路49号

　　网址链接： http://www.bysy.edu.cn/xxgnk/index.shtml

　　

　　

　　Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides，Ministry of Health (Peking University Third Hospital)

 

　　Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides，Ministry of Health (former Key Laboratory of Heart and Lung Endocrine-regulating Peptide,Ministry of Health) was established in 1984, passed the acceptance in 1986 and opened to the whole country. Former laboratory director are Professor Tang Jian, and Academician Han Qide. Honorary director of the laboratory is Academician Han Qide, the current laboratory director is Professor Gao Wei, academic committee director is Academician Zhang Yun.

　　The main research directions of our laboratory are the prevention and treatment of risk factors of coronary heart disease and the diagnosis and rehabilitation / translational medicine of coronary heart disease and its complications. By application of clinical and fundamental bi-directional conjugation research in translational medicine, our research focuses on the molecular mechanisms of disease risk, causing factors of disease occurrence and development. Mainly include 1) early prevention: to reveal coronary heart disease and its complications susceptibility genes and new risk factors; 2) early prediction: new early biomarkers to identify coronary heart disease and its complications; 3) early treatment: to deepen the study of new technologies, new methods and new targets for treating of coronary heart disease and its complications ; 4) early rehabilitation: elucidate the protective effect and mechanism of rehabilitation training on coronary heart disease and its complications, put forward the early prediction, early diagnosis, early treatment, early recovery program to develop new technologies and new drugs targets for disease prevention and treatment to provide scientific basis and new strategies for reducing the incidence of cardiovascular events in China and improving the quality of life of patients with cardiovascular diseases.

　　The structure of laboratory personnel: The existing fixed staff of 60, including 52full-time scientific researchers, 8 technicians; 2 Changjiang Scholars, selected NSFC outstanding youth project of 4, outstanding youth project of 3, 1 person from Beijing Science and Technology Rising Star, 1 from "Ten thousand plan" - National high level talents special support plan; 26 senior senior titles, 19 associate professorships, 49 doctoral degree holders, 7 master degree holders; more than 20 with postdoctoral or visiting scholar experience abroad. For a long time, the academic level of PI in our laboratories has been recognized and valued by academics both at home and abroad. Many people have been elected as chairpersons, vice chairmen and secretary general of international and domestic academic organizations. Many people have been employed as editors of international and domestic publications.

　　Laboratory construction area of ？？2140m², total equipment value of more than 30 million yuan. In recent years, our laboratory has established and improved a number of research platforms, including morphological imaging platforms (including histomorphological platforms and cellular imaging platforms), biochemical metabolism detection technology platforms, proteomics / metabolomics detection technology platforms, and cardiovascular model function evaluation platforms (Echocardiography, vascular tone physiological recording system, etc.). In clinical research, we have established and improved the cardiopulmonary rehabilitation evaluation platform, cardiovascular disease clinical research platform, cardiovascular disease biobank.

　　In recent years, key laboratories have obtained the first prize of "2015 Huaxia Medical Science and Technology Award", the second prize of National Natural Science Award 2017 and the first prize of Natural Science Award of Ministry of Education in 2017; two PI successively won the "WuXi PharmaDeal of Life Chemistry Research Award" scholar award.

　　In the prevention and treatment of coronary heart disease risk factors, the results of the research on the prevention and treatment of hyperhomocysteinemia and atherosclerosis provide experimental evidence that Chinese people have high homocysteinemia as the risk factor of vascular disease , and meanwhile transformed into clinical research, carried out the 12th Five-year project "Chinese population coronary heart disease optimization treatment", make outstanding contributions to the optimal treatment of coronary heart disease patients in our country. In the field of diagnosis, rehabilitation and translational medicine research of coronary heart disease and its complications, we focus on the molecular mechanisms of cardiovascular receptor and disease development, early molecular mechanisms of heart failure and potential biomarker for diagnosis and treatment of disease, at all levels from the diagnosis and early prediction of coronary heart disease and heart failure to carry out fundamental and clinical research to develop new technologies, drugs and new targets can be used for disease prevention and treatment, in order to provide a scientific basis and new strategies to reduce the incidence of cardiovascular events in China and improve quality of life of cardiovascular disease patients.

　　

　　Director: Wei Gao

　　Contact: Haiyi Yu

　　Email: bysyxnk@163.com

　　Office: 010-82266711

　　Address: Institute of vascular medicine，Peking University Third Hospital，49 Huayuan North Road，Haidian District，Beijing，100191，P. R. China.

　　http://www.bysy.edu.cn/xxgnk/index.shtml